Interleukin-6 in the Bone Marrow Microenvironment Promotes the Growth and Survival of Neuroblastoma Cells

Overview

Journal Cancer Res

Specialty Oncology

Date 2009 Jan 2

PMID 19118018

Citations 95

Authors

Tasnim Ara

Liping Song

Hiroyuki Shimada

Nino Keshelava

Heidi V Russell

Leonid S Metelitsa

Susan G Groshen

Robert C Seeger

Yves A DeClerck

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma, the second most common solid tumor in children, frequently metastasizes to the bone marrow and the bone. Neuroblastoma cells present in the bone marrow stimulate the expression of interleukin-6 (IL-6) by bone marrow stromal cells (BMSC) to activate osteoclasts. Here we have examined whether stromal-derived IL-6 also has a paracrine effect on neuroblastoma cells. An analysis of the expression of IL-6 and its receptor, IL-6R, in 11 neuroblastoma cell lines indicated the expression of IL-6 in 4 cell lines and of IL-6R in 9 cell lines. Treatment of IL-6R-positive cells with recombinant human IL-6 resulted in signal transducer and activator of transcription-3 and extracellular signal-regulated kinase-1/2 activation. Culturing IL-6R-positive neuroblastoma cells in the presence of BMSC or recombinant human IL-6 increased proliferation and protected tumor cells from etoposide-induced apoptosis, whereas it had no effect on IL-6R-negative tumor cells. In vivo, neuroblastoma tumors grew faster in the presence of a paracrine source of IL-6. IL-6 induced the expression of cyclooxygenase-2 in neuroblastoma cells with concomitant release of prostaglandin-E2, which increased the expression of IL-6 by BMSC. Supporting a role for stromal-derived IL-6 in patients with neuroblastoma bone metastasis, we observed elevated levels of IL-6 in the serum and bone marrow of 16 patients with neuroblastoma bone metastasis and in BMSC derived from these patients. Altogether, the data indicate that stromal-derived IL-6 contributes to the formation of a bone marrow microenvironment favorable to the progression of metastatic neuroblastoma.

Citing Articles

Mesenchymal stromal cells as cancer promoters.

Antoon R, Overdevest N, Saleh A, Keating A Oncogene. 2024; 43(49):3545-3555.

PMID: 39414984 PMC: 11602730. DOI: 10.1038/s41388-024-03183-1.

Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges.

Pathania A Cancers (Basel). 2024; 16(12).

PMID: 38927907 PMC: 11201451. DOI: 10.3390/cancers16122201.

Nuclear factor-κB activation by transforming growth factor-β1 drives tumour microenvironment-mediated drug resistance in neuroblastoma.

Louault K, Blavier L, Lee M, Kennedy R, Fernandez G, Pawel B Br J Cancer. 2024; 131(1):90-100.

PMID: 38806726 PMC: 11231159. DOI: 10.1038/s41416-024-02686-8.

Study on the mechanism of CXCL12/CXCR4-axis-mediated upregulation of IL-8 and IL-6 on the biological function of acute T lymphocyte leukaemia cells.

Zhou L, Zhao H, Zhang C, Chen Z, Li D, Qian G Cytotechnology. 2024; 76(1):97-111.

PMID: 38304623 PMC: 10828134. DOI: 10.1007/s10616-023-00600-3.

Biological Insight and Recent Advancement in the Treatment of Neuroblastoma.

Rivera Z, Escutia C, Madonna M, Gupta K Int J Mol Sci. 2023; 24(10).

PMID: 37239815 PMC: 10218416. DOI: 10.3390/ijms24108470.

References

Roskelley C, Bissell M . The dominance of the microenvironment in breast and ovarian cancer. Semin Cancer Biol. 2002; 12(2):97-104. PMC: 3771861. DOI: 10.1006/scbi.2001.0417. View

Giuliani N, Lunghi P, Morandi F, Colla S, Bonomini S, Hojden M . Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia. 2004; 18(3):628-35. DOI: 10.1038/sj.leu.2403269. View

Hirano T, Ishihara K, Hibi M . Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000; 19(21):2548-56. DOI: 10.1038/sj.onc.1203551. View

Prockop D . Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997; 276(5309):71-4. DOI: 10.1126/science.276.5309.71. View

Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B . Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science. 1988; 241(4867):825-8. DOI: 10.1126/science.3136546. View

Kallen K . The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta. 2002; 1592(3):323-43. DOI: 10.1016/s0167-4889(02)00325-7. View

Murray P . The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007; 178(5):2623-9. DOI: 10.4049/jimmunol.178.5.2623. View

Hazlehurst L, Landowski T, Dalton W . Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene. 2003; 22(47):7396-402. DOI: 10.1038/sj.onc.1206943. View

Damiano J, Cress A, Hazlehurst L, Shtil A, Dalton W . Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999; 93(5):1658-67. PMC: 5550098. View

10.

Brodeur G . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3(3):203-16. DOI: 10.1038/nrc1014. View

11.

Kaplan R, Rafii S, Lyden D . Preparing the "soil": the premetastatic niche. Cancer Res. 2006; 66(23):11089-93. PMC: 2952469. DOI: 10.1158/0008-5472.CAN-06-2407. View

12.

Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J . 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol. 2007; 72(5):1137-45. DOI: 10.1124/mol.107.038117. View

13.

Tas F, Oguz H, Argon A, Duranyildiz D, Camlica H, Yasasever V . The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Med Oncol. 2005; 22(3):241-6. DOI: 10.1385/MO:22:3:241. View

14.

Alhadlaq A, Mao J . Mesenchymal stem cells: isolation and therapeutics. Stem Cells Dev. 2004; 13(4):436-48. DOI: 10.1089/scd.2004.13.436. View

15.

Jones S, Horiuchi S, Topley N, Yamamoto N, Fuller G . The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 2001; 15(1):43-58. DOI: 10.1096/fj.99-1003rev. View

16.

Liotta L, Kohn E . The microenvironment of the tumour-host interface. Nature. 2001; 411(6835):375-9. DOI: 10.1038/35077241. View

17.

Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M . Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2005; 28(3):231-8. DOI: 10.1385/CRIAI:28:3:231. View

18.

Dubois S, Kalika Y, Lukens J, Brodeur G, Seeger R, Atkinson J . Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999; 21(3):181-9. DOI: 10.1097/00043426-199905000-00005. View

19.

Ara T, DeClerck Y . Mechanisms of invasion and metastasis in human neuroblastoma. Cancer Metastasis Rev. 2006; 25(4):645-57. DOI: 10.1007/s10555-006-9028-9. View

20.

Horiguchi A, Oya M, Marumo K, Murai M . STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int. 2002; 61(3):926-38. DOI: 10.1046/j.1523-1755.2002.00206.x. View